bionity.com

𝗔 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿 𝗛𝗖𝗩 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵: The only natural host of the hepatitis C virus (HCV) is humans. Model organisms for laboratory studies, especially mice, cannot be infected which makes the search for a vaccine against HCV extremely difficult because the protective effect cannot be tested directly. In order to understand why the virus cannot infect mice and to enable the development of new animal models, researchers at TWINCORE GmbH in Hannover have generated an adapted virus variant that can infect mouse liver cells in vitro. They have now published their work in the ‘Journal of Hepatology Reports’. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/dj8CYS8r Julie Sheldon, Thomas Pietschmann, Melina Winkler, Qinggong Yuan, Dr. rer. nat. Nicola F., Csaba Miskey, Dr. Jan Grabowski

𝗕𝗮𝘁𝘀: 𝗖𝗼𝗿𝗼𝗻𝗮 𝗪𝗶𝘁𝗵𝗼𝘂𝘁 𝗦𝘆𝗺𝗽𝘁𝗼𝗺𝘀: Bats have the ability to tolerate coronaviruses and other viruses without becoming ill. This is due to special adaptations in their immune system. As part of the “Bat1K” project, an international research team has now generated high-quality genomes of bats in order to analyze these adaptations. The study, published in the scientific journal “Nature,” shows that bats have more genetic adaptations in their immune genes than other mammals. The ISG15 gene, in particular, plays a key role: in some bats, it can reduce the production of SARS-CoV-2 viruses by up to 90 percent. The results could help to develop new medical approaches to combat viral diseases. Bats are fascinating due to their unique characteristics. As the only mammals capable of flight, they play an important role in the ecosystem: they pollinate plants, spread seeds, and contribute to the balance of insect populations with their feeding habits. Thanks to their exceptional orientation by means of ultrasonic echolocation, they are ideally adapted to their nocturnal lifestyle. “In addition, bats are also of great interest for medical research: The analysis of their immune system and their unique viral tolerance can provide valuable insights for the development of new therapies and drugs,” explains Prof. Dr. Michael Hiller, spokesperson of the former Hessian LOEWE Center for Translational Biodiversity Genomics and Professor of Comparative Genomics at Frankfurt’s Goethe University and the Senckenberg Research Institute and Natural History Museum Frankfurt, and he continues, “They are also known to carry numerous viruses, including those that are transmissible to humans, such as coronaviruses. However, it is interesting to note that bats do not show any symptoms of disease when infected with such viruses.” 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/dR4GRnuG Senckenberg Nature Research, Arinjay Banerjee, Judith Jördens

𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝘁𝗵𝗼𝘂𝘀𝗮𝗻𝗱𝘀 𝗼𝗳 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀 𝗼𝗻 𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺: Researchers at the Universität Basel are able to test the effects of more than 1,500 compounds on cell metabolism in parallel. Their analysis also led to the discovery of previously unknown mechanisms for known drugs. This approach could help scientists better predict side effects and find additional uses for commercially available medications. How do active substances alter metabolic processes in cells? Answering that question would provide valuable clues for the development of new medications. However, investigating such modes of action for a whole compound library would have been very resource-intensive in the past. Researchers at the Department of Biomedicine at the University of Basel have just presented a method of testing the metabolic effects of thousands of active substances at the same time. They have published the results of this method, known as high-throughput metabolomics, in the scientific journal Nature Biotechnology. “When we have a better understanding of exactly how active substances intervene in cell metabolism, the development of medication can be accelerated,” explains Professor Mattia Zampieri. “Our method provides additional characterization of the substances, from which we can infer possible side effects or interactions with other medications.” 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/dUGsd3gA Laurentz Schuhknecht, Jürgen Jänes, Martina Bläsi, Eleni Panoussis, Sebastian Bors, Terézia Dorčáková, Pedro Beltrao

👉 All 𝗠𝗮𝘀𝘀 𝗦𝗽𝗲𝗸𝘁𝗿𝗼𝗺𝗲𝘁𝗲𝗿 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿𝘀 🔬 on your favourite portal bionity.com from KNAUER , Thermo Fisher Scientific , Analytik Jena and over 95 other manufacturers ... https://lnkd.in/e6v9R8ES LUMITOS AG, chemie.de, chemeurope.com yumda.com

𝗡𝗲𝘄 𝗻𝘂𝗺𝗯𝗲𝗿𝗶𝗻𝗴 𝘀𝘆𝘀𝘁𝗲𝗺 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗮𝘁𝗲𝘀 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗼𝗺𝗮𝗶𝗻𝘀: Adhesion GPCRs are a group of cell-surface sensors associated with many body functions and diseases. However, they are not yet sufficiently understood to be exploited for therapies. Collaborative Research Centre (CRC) 1423 at Leipzig University aims to change this. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eA3dYAwv Universität Leipzig, Peter Hildebrand, Florian Seufert

𝗛𝗶𝗴𝗵-𝗧𝗲𝗰𝗵 𝗠𝗶𝗰𝗿𝗼𝘀𝗰𝗼𝗽𝘆 𝗘𝗻𝗮𝗯𝗹𝗲𝘀 𝗧𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝗥𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: Researchers at CeMM and the Medical University of Vienna have developed an innovative microscopy-based approach that could predict the best approved drug to treat individual rheumatoid arthritis patients using samples of their blood. Published in the Lancet group journal EBioMedicine, the study demonstrates the feasibility of precision medicine to significantly enhance treatments for rheumatoid arthritis and likely other autoimmune diseases. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eyNHzdVm Giulio Superti-Furga , Felix Kartnig,  Leonhard Heinz, CeMM

𝗪𝗮𝗰𝗸𝗲𝗿 𝗖𝗵𝗲𝗺𝗶𝗲 𝗔𝗚: 𝗖𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗱𝗶𝘃𝗶𝘀𝗶𝗼𝗻𝘀 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗲𝗱 𝗶𝗻 𝗮 𝘄𝗲𝗮𝗸 𝗺𝗮𝗿𝗸𝗲𝘁 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁 𝗶𝗻 𝟮𝟬𝟮𝟰: Wacker Chemie AG achieved good results in 2024 given a persistently weak market environment. Overall, sales and earnings were below the previous year's figures. This development was driven primarily by lower prices and much lower volumes at POLYSILICON. Despite headwinds, the chemical divisions achieved sales at the previous year's level and earnings in total even exceeded the previous year's figure. Sales and earnings in the biotechnology division were up year over year. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eaqJ6F3U WACKER, Christian Hartel

𝗟𝗜𝗠𝗔𝗔 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗮𝗻𝗱 𝗟𝗮𝗯𝗼𝗿 𝗕𝗲𝗰𝗸𝗲𝗿 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽: LIMAA Technologies, an innovative deep-tech startup in the field of medical technology solutions, is proud to announce a strategic partnership with Labor Becker, one of Germany’s largest and owner-managed diagnostic laboratories. The collaboration is set to accelerate the development of LIMAA's end-to-end histopathology platform, enhancing scalability and precision in tissue diagnostics, including integrated genomics. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/emKnkJPU LIMAA Technologies, Fabian Mohr, Labor Becker MVZ eGbR, Marc Becker, Lisa-Marie Stumpf

𝗦𝗔𝗥𝗦-𝗖𝗼𝗩-𝟮: 𝗖𝗲𝗹𝗹 𝗽𝗵𝗼𝗻𝗲 𝗮𝗻𝗱 𝗴𝗲𝗻𝗼𝗺𝗲 𝗱𝗮𝘁𝗮 𝗮𝗹𝗹𝗼𝘄 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗿𝗮𝗰𝗶𝗻𝗴 𝗼𝗳 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗽𝗮𝘁𝗵𝘄𝗮𝘆𝘀: To track the spread of pathogens such as SARS-CoV-2 in a more targeted manner, anonymized mobile phone data and other metadata (such as zip codes) can be combined with genome data. A systematic evaluation of such combined data pools has now been presented by scientists from the Jena-based start-up nanozoo GmbH and Jena University Hospital (UKJ) - both partners in the InfectoGnostics Research Campus Jena. The team has published the results of the study under the title "Leveraging mobility data to analyze persistent SARS-CoV-2 mutations and inform targeted genomic surveillance" in the open access journal eLife. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eQ7SpwPX InfectoGnostics Research Campus Jena, nanozoo, Friedrich-Schiller-Universität Jena, Universitätsklinikum Jena

𝗡𝗼𝘃𝗲𝗹 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀 𝘁𝗼 𝗼𝘃𝗲𝗿𝗰𝗼𝗺𝗲 𝗮𝗻𝘁𝗶𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗹𝘂𝗻𝗴 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the cystic fibrosis antimicrobial resistance (CF AMR) Syndicate with funding from the medical research charity, LifeArc . Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to overcome antimicrobial-resistant lung infections in people with cystic fibrosis (CF). 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eAGEBsiX GLOX Therapeutics Ltd., James Clark, catherine kettleborough, Beverley Isherwood, Paula Sommer, CF AMR Syndicate, Cystic Fibrosis Trust, Medicines Discovery Catapult, Michelle Ricketts, PhD